Global Orphan Diseases Partnering Deal Trends, Players and Financials Analysis 2014-2019

DUBLIN, March 20, 2019 /PRNewswire/ — The “Global Orphan Diseases Partnering 2014-2019: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.

Global Orphan Diseases Partnering 2014 to 2019 provides the full collection of Orphan Diseases disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Orphan Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Orphan Diseases deals.

The report presents financial deal terms values for Orphan Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Orphan Diseases dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Orphan Diseases dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Orphan Diseases deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Orphan Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Orphan Diseases deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Orphan Diseases partnering deals by specific Orphan Diseases target announced since 2014. The chapter is organized by specific Orphan Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Orphan Diseases partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Orphan Diseases partnering and dealmaking since 2014.

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Orphan Diseases dealmaking

2.1. Introduction

2.2. Orphan Diseases partnering over the years

2.3. Orphan Diseases partnering by deal type

2.4. Orphan Diseases partnering by industry sector

2.5. Orphan Diseases partnering by stage of development

2.6. Orphan Diseases partnering by technology type

2.7. Orphan Diseases partnering by therapeutic indication

Chapter 3 -Financial deal terms for Orphan Diseases partnering

3.1. Introduction

3.2. Disclosed financials terms for Orphan Diseases partnering

3.3. Orphan Diseases partnering headline values

3.4. Orphan Diseases deal upfront payments

3.5. Orphan Diseases deal milestone payments

3.6. Orphan Diseases royalty rates

Chapter 4 – Leading Orphan Diseases deals and dealmakers

4.1. Introduction

4.2. Most active in Orphan Diseases partnering

4.3. List of most active dealmakers in Orphan Diseases

4.4. Top Orphan Diseases deals by value

Chapter 5 – Orphan Diseases contract document directory

5.1. Introduction

5.2. Orphan Diseases partnering deals where contract document available

Chapter 6 – Orphan Diseases dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Orphan Diseases therapeutic target

Appendices

Appendix 1 – Directory of Orphan Diseases deals by company A-Z 2014 to 2019

Appendix 2 – Directory of Orphan Diseases deals by deal type 2014 to 2019

Appendix 3 – Directory of Orphan Diseases deals by stage of development 2014 to 2019

Appendix 4 – Directory of Orphan Diseases deals by technology type 2014 to 2019

  • Further reading on dealmaking
  • Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/research/xfmb9s/global_orphan?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

WHAT TO READ NEXT...